Koenzim Q10’un ratlarda sıçanlarda sisplatinin neden olduğu ototoksisiteye etkisi
Abstract
Objective: To determine the efficacy of systemic administration of coenzyme Q10 at low and high doses on cisplatin-induced ototoxicity in rats.
Methods: Our study was performed with 40 Sprague-Dawley rats. They were divided randomly into five groups: Cis, Cis+Q1030, Cis+Q1010, Q10, and control. Cis (n=8) group was administered cisplatin [a single intraperitoneal (i.p.) injection of 14 mg/kg], Cis+Q1030 (n=8) group was administered cisplatin (a single i.p. injection of 14 mg/kg) and
coenzyme Q10 (30 mg/kg/day, i.p.) for 3 days, Cis+Q1010 (n=8) group was given cisplatin (a single dose of 14 mg/kg/day, i.p.) and coenzyme Q10 (10 mg/kg/day, i.p.) for 3 days, Q10 (n=8) group was administered coenzyme Q10 (10 mg/kg/day, i.p.) for 3 days and Group C (n=8) (control group) was administered saline solution (1 mL/day, i.p.) once daily for 3 days. Pretreatment and posttreatment hearing levels were evaluated with distortion product otoacoustic emissions (DPOAEs).
Results: There was no statistically significant difference in the results of measurements of 4004, 4358, 4761 and 5188 Hz at end of the study in comparison to baseline (p>0.05). On the other hand, there was a significant
difference at the measurements of 5652, 6165, 7336 and 7996 Hz (p=0.002, p=0.037, p=0.001, p=0.001, respectively). The rate of change at 5652 Hz revealed that Cis group was different from Cis+Q1010, control and Q10 groups (p<0.01); measurements at 6165 Hz revealed that change at Cis group was significantly different from control and Q10 groups (p<0.01, p<0.05). Final measurements of decrease in Cis group at 7336 and 7996 Hz were significantly different from baseline (p<0.05; p<0.01).
Conclusion: The high-dose coenzyme Q10 showed a protective effect on hearing in cisplatin-induced ototoxicity while low-dose coenzyme Q10 protected hearing at low frequencies but did not show protective effect at high frequencies.
Keywords
References
- 1. Walker EM Jr, Fazekas-May MA, Bowen WR. Nephrotoxic and ototoxic agents. Clin Lab Med 1990;10:323–54.
- 2. Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 1995;76:386–94.
- 3. Daldal A, Odabasi O, Serbetcioglu B. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg 2007;137:747–52.
- 4. Rybak LP, Whitworth CA, Mukherjea D, Ramkuvar L. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007;226:157–67.
- 5. Van den Berg JH, Beijnen JH, Balm AJ, Schellens JH. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev 2006;32:390–7.
- 6. Fetoni AR, Sergi B, Ferraresi A, Paludetti G, Troiani D. Protective effects of alpha-tocopherol and tiopronin against cisplatin- induced ototoxicity. Acta Otolaryngol 2004;124:421–6.
- 7. Ise T, Shimizu T, Lee EL, Inoue H, Kohno K, Okada Y. Roles of volume-sensitive Cl-channel in cisplatin-induced apoptosis in human epidermoid cancer cells. J Membr Biol 2005;205:139–45.
- 8. Van Ruijven MW, de Groot JC, Klis SF, Smoorenbug GF. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res 2005;205:241–8.
Details
Primary Language
Turkish
Subjects
Health Care Administration
Journal Section
Research Article
Authors
Güler Berkiten
This is me
Tolgar Lütfi Kumral
This is me
Ziya Saltürk
This is me
Belgin Tutar
This is me
Ayşe Enise Göker
This is me
Gürcan Sünnetçi
This is me
Yavuz Uyar
This is me
Hilmi Uğraş
This is me
Publication Date
December 31, 2016
Submission Date
July 24, 2017
Acceptance Date
-
Published in Issue
Year 2016 Volume: 6 Number: 3